Clinical characteristics of HIV-infected patients with adjudicated heart failure

European Journal of Preventive Cardiology

Volumn 24, Issue 16, 2017, Pages 1746-1758

  Steverson, Alexandra B ^a   Pawlowski, Anna E ^a   Schneider, Daniel ^a   Nannapaneni, Prasanth ^a   Sanders, Jes M ^a   Achenbach, Chad J ^a   Shah, Sanjiv J ^a   Lloyd Jones, Donald M ^a   Feinstein, Matthew J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adjudication; electronic cohort; Heart failure; HIV

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE SIZE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ICD-10; ICD-9; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; VIREMIA; VIRUS LOAD; CAUSE OF DEATH; COMPLICATION; DIAGNOSTIC IMAGING; FOLLOW UP; HOSPITAL; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRENDS; UNITED STATES;

CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC IMAGING; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HIV; HIV INFECTIONS; HOSPITALS, URBAN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 85032886665     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487317732432     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2014. HIV Surveillance Report. Atlanta, USA: CDC, 2015
2. Palella FJ, Jr Baker RK, Moorman AC, Investigators HIVOS. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27–34.
3. Feinstein MJ, Bahiru E, Achenbach C, Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol 2015; 117: 214–220.
4. Trickey A, May MT, Vehreschild J, Antiretroviral Therapy Cohort Collaboration. Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. PLoS One 2016; 11: e0160460–e0160460.
5. Butt AA, Chang CC, Kuller L, Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011; 171: 737–743.
6. Paisible A-L, Chang C-CH, So-Armah KA, HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 2015; 68: 209–216.
7. Hsu JC, Li Y, Marcus GM, Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 2013; 61: 2288–2295.
8. Tseng ZH, Secemsky EA, Dowdy D, Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59: 1891–1896.
9. Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med 2013; 34: 283–292.
10. Friis-Moller N, Ryom L, Smith C, on behalf of the D:A:D Study Group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prevent Cardiol 2016; 23: 214–223.
11. Idris NS, Grobbee DE, Burgner D, Cardiovascular manifestations of HIV infection in children. Eur J Prevent Cardiol 2015; 22: 1452–1461.
12. Levy WS, Simon GL, Rios JC, Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 1989; 63: 86–89.
13. De Castro S, d’Amati G, Gallo P, Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 1994; 24: 1018–1024.
14. Herskowitz A, Vlahov D, Willoughby S, Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. J Am Coll Cardiol 1993; 71: 955–958.
15. Manga P, McCutcheon K, Tsabedze N, HIV and nonischemic heart disease. J Am Coll Cardiol 2017; 69: 83–91.
16. Vachiat A, McCutcheon K, Tsabedze N, HIV and ischemic heart disease. J Am Coll Cardiol 2017; 69: 73–82.
17. Al-Kindi SG, El Amm C, Ginwalla M, Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. Int J Cardiol 2016; 218: 43–46.
18. Freiberg MS, Chang CH, Skanderson M, Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol 2017; 2: 536–546.
19. Hsue PY, Hunt PW, Ho JE, Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3: 132–139.
20. Holloway CJ, Ntusi N, Suttie J, Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation 2013; 128: 814–822.
21. Diaz-Zamudio M, Dey D, LaBounty T, Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study. J Cardiovasc Magn Reson 2015; 17: 91–91.
22. Janjua SA, Triant VA, Addison D, HIV infection and heart failure outcomes in women. J Am Coll Cardiol 2017; 69: 107–108.
23. Rosamond WD, Chang PP, Baggett C, Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail 2012; 5: 152–159.
24. Goff DC, Jr Pandey DK, Chan FA, Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000; 160: 197–202.
25. Felsen UR, Bellin EY, Cunningham CO, Development of an electronic medical record-based algorithm to identify patients with unknown HIV status. AIDS Care 2014; 26: 1318–1325.
26. Moorman AC, Gordon SC, Rupp LB, for the Chronic Hepatitis Cohort Study Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis 2013; 56: 40–50.
27. Wilke RA, Berg RL, Peissig P, Use of an electronic medical record for the identification of research subjects with diabetes mellitus. Clin Med Res 2007; 5: 1–7.
28. Ali S, Rouse A. Practice audits: reliability of sphygmomanometers and blood pressure recording bias. J Hum Hypertens 2002; 16: 359–361.
29. Myers MG, Godwin M, Dawes M, Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010; 55: 195–200.
30. Quan H, Li B, Saunders LD, IMECCHI Investigators. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008; 43: 1424–1441.
31. Rouse A, Marshall T. The extent and implications of sphygmomanometer calibration error in primary care. J Hum Hypertens 2001; 15: 587–591.
32. Ives DG, Fitzpatrick AL, Bild DE, Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995; 5: 278–285.
33. Bozzette SA, Ake CF, Tam HK, Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702–710.
34. Lee DS, Donovan L, Austin PC, Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 2005; 43: 182–188.
35. McCormick N, Lacaille D, Bhole V, Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS One 2014; 9: e92286–e92286.
36. Patel AB, Quan H, Welsh RC, Validity and utility of ICD-10 administrative health data for identifying ST- and non-ST-elevation myocardial infarction based on physician chart review. CMAJ Open 2015; 3: E413–E418.
37. Shah SJ, Katz DH, Selvaraj S, Phenomapping for novel classification of heart failure with preserved ejection fraction: clinical perspective. Circulation 2015; 131: 269–279.
38. Iribarren C, Tolstykh IV, Miller MK, Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol 2012; 176: 1014–1024.
39. Saczynski JS, Andrade SE, Harrold LR, A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Safe 2012; 21(Suppl 1): 129–140.
40. Kim HN, Januzzi JL, Jr. Natriuretic peptide testing in heart failure. Circulation 2011; 123: 2015–2019.
41. Opdahl A, Ambale Venkatesh B, Fernandes VR, Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2014; 63: 1182–1189.
42. Chahal H, Bluemke DA, Wu CO, Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis. Heart 2015; 101: 58–64.
43. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670–679.
44. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 16: 233–270
45. Cannillo M, D’Ascenzo F, Grosso Marra W, Heart failure in patients with human immunodeficiency virus: a review of the literature. J Cardiovasc Med 2015; 16: 383–389.
46. Remick J, Georgiopoulou V, Marti C, Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. Circulation 2014; 129: 1781–1789.
47. Choi AI, Vittinghoff E, Deeks SG, Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25: 1289–1298.
48. Price J, Hoy J, Ridley E, Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health 2015; 12: 240–248.
49. Secemsky EA, Scherzer R, Nitta E, Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals. JACC Heart Fail 2015; 3: 591–599.
50. Blaylock JM, Byers DK, Gibbs BT, Longitudinal assessment of cardiac diastolic function in HIV-infected patients. Int J STD AIDS 2012; 23: 105–110.
51. Cerrato E, D’Ascenzo F, Biondi-Zoccai G, Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34: 1432–1436.
52. Triant VA, Lee H, Hadigan C, Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506–2512.